Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.62 USD | +0.28% | -2.41% | +15.34% |
Mar. 01 | RBC Raises Price Target on Zynex to $15 From $13, Keeps Outperform Rating | MT |
Feb. 29 | Zynex, Inc. Provides Earnings Guidance First Quarter and Full Year 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's profit outlook over the next few years is a strong asset.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.34% | 405M | C | ||
+9.21% | 221B | B | ||
+7.72% | 184B | B- | ||
+18.32% | 142B | B- | ||
+18.66% | 101B | A- | ||
+8.25% | 68.07B | A- | ||
+24.85% | 57.27B | B+ | ||
-2.49% | 47.42B | B+ | ||
+5.35% | 43.19B | A | ||
+14.98% | 28.84B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Zynex, Inc. - Nasdaq
- Ratings Zynex, Inc.